How to buy Lixte Biotechnology stock

Lixte Biotechnology Holdings, Inc is a biotechnology business based in the US. Lixte Biotechnology shares (LIXT) are listed on the NASDAQ and all prices are listed in US Dollars. Lixte Biotechnology employs 3 staff and has a market cap (total outstanding shares value) of 0.00.

Lixte Biotechnology share price

Use our graph to track the performance of LIXT stocks over time.

Lixte Biotechnology shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$2.36 - $7.14
50-day moving average	$3.23
200-day moving average	$3.02
Wall St. target price	N/A
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.04

Buy Lixte Biotechnology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Lixte Biotechnology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Lixte Biotechnology Holdings, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lixte Biotechnology financials

Gross profit TTM	$0
Return on assets TTM	-51.68%
Return on equity TTM	-87.69%
Profit margin	0%
Book value	$0.12
Market capitalisation	$39.1 million

TTM: trailing 12 months

Shorting Lixte Biotechnology shares

There are currently 15,290 Lixte Biotechnology shares held short by investors – that's known as Lixte Biotechnology's "short interest". This figure is 62.7% down from 41,026 last month.

There are a few different ways that this level of interest in shorting Lixte Biotechnology shares can be evaluated.

Lixte Biotechnology's "short interest ratio" (SIR)

Lixte Biotechnology's "short interest ratio" (SIR) is the quantity of Lixte Biotechnology shares currently shorted divided by the average quantity of Lixte Biotechnology shares traded daily (recently around 254833.33333333). Lixte Biotechnology's SIR currently stands at 0.06. In other words for every 100,000 Lixte Biotechnology shares traded daily on the market, roughly 60 shares are currently held short.

To gain some more context, you can compare Lixte Biotechnology's short interest ratio against those of similar companies.

• Amgen (AMGN.US): 3.93
• BeiGene (BGNE.US): 10.55
• BioNTech (BNTX.US): 2.56

However Lixte Biotechnology's short interest can also be evaluated against the total number of Lixte Biotechnology shares, or, against the total number of tradable Lixte Biotechnology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lixte Biotechnology's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Lixte Biotechnology shares in existence, roughly 0 shares are currently held short) or 0.0029% of the tradable shares (for every 100,000 tradable Lixte Biotechnology shares, roughly 3 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Lixte Biotechnology.

Find out more about how you can short Lixte Biotechnology stock.

Lixte Biotechnology share dividends

We're not expecting Lixte Biotechnology to pay a dividend over the next 12 months.

You may also wish to consider:

• Amgen (AMGN.US) (2.79% forward annual dividend yield)

Have Lixte Biotechnology's shares ever split?

Lixte Biotechnology's shares were split on a 1:6 basis on 19 November 2020. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lixte Biotechnology shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Lixte Biotechnology shares which in turn could have impacted Lixte Biotechnology's share price.

Lixte Biotechnology share price volatility

Over the last 12 months, Lixte Biotechnology's shares have ranged in value from as little as $2.36 up to $7.14. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lixte Biotechnology's is -0.9967. This would suggest that Lixte Biotechnology's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Lixte Biotechnology has bucked the trend.

To put Lixte Biotechnology's beta into context you can compare it against those of similar companies.

• Amgen (AMGN.US): 0.7352
• BeiGene (BGNE.US): 0.9162

Lixte Biotechnology overview

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures, which might be useful in the treatment of cancers, and vascular and metabolic diseases; and LB-200 series for the treatment of chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc. ; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; pharmacologic study with the National Cancer Institute; and clinical research support agreement with City of Hope National Medical Center to carry out a Phase 1b clinical trial of its LB-100, a protein phosphatase inhibitor for small cell lung cancer.

Frequently asked questions

• What percentage of Lixte Biotechnology is owned by insiders or institutions?

  Currently 68.476% of Lixte Biotechnology shares are held by insiders and 9.651% by institutions.

• How many people work for Lixte Biotechnology?

  Latest data suggests 3 work at Lixte Biotechnology.

• When does the fiscal year end for Lixte Biotechnology?

  Lixte Biotechnology's fiscal year ends in December.

• Where is Lixte Biotechnology based?

  Lixte Biotechnology's address is: 248 Route 25A, No. 2, East Setauket, NY, United States, 11733